Friday, August 15 7:30–9:15am
P.A.C.T. Update: Practical Approaches to Comprehensive Treatment of Pain 2024-2025 (Part 1)
Friday, August 15 10:15am–12:30pm
P.A.C.T. Update: Practical Approaches to Comprehensive Treatment of Pain 2024-2025 (Part 2)
Thursday, August 14 8:30–9:30am
Brain Check: Promoting Brain Health and Detecting Cognitive Impairment
Friday, August 15 7:30–9:15am
P.A.C.T. Update: Practical Approaches to Comprehensive Treatment of Pain 2024-2025 (Part 1)
Friday, August 15 10:15am–12:30pm
P.A.C.T. Update: Practical Approaches to Comprehensive Treatment of Pain 2024-2025 (Part 2)
Friday, August 15 7:30–9:15am
P.A.C.T. Update: Practical Approaches to Comprehensive Treatment of Pain 2024-2025 (Part 1)
Friday, August 15 10:15am–12:30pm
P.A.C.T. Update: Practical Approaches to Comprehensive Treatment of Pain 2024-2025 (Part 2)
Friday, August 15 7:30–9:15am
P.A.C.T. Update: Practical Approaches to Comprehensive Treatment of Pain 2024-2025 (Part 1)
Friday, August 15 10:15am–12:30pm
P.A.C.T. Update: Practical Approaches to Comprehensive Treatment of Pain 2024-2025 (Part 2)
Thursday, August 14 3:30–4:15pm
Skin Deep: Tackling Everyday Dermatologic Cases in Primary Care
Thursday, August 14 4:30–6pm
Taking the Dialogue to the Next Level: Facilitating Open Communication About Obesity
Thursday, August 14 8:30–9:30am
Brain Check: Promoting Brain Health and Detecting Cognitive Impairment
Thursday, August 14 7:30–8:30am
Thursday, August 14 4:30–6pm
Taking the Dialogue to the Next Level: Facilitating Open Communication About Obesity
Friday, August 15 1:30–2:30pm
Cardiology in Focus: Breaking Down the Latest Guideline Updates
Financial Disclosures
- Charles E. Argoff, MD, FABPM
- Researcher: AbbVie; Speaker: AbbVie, Lilly, Scilex, Lundbeck, Averitas Pharma, Teva, Impel, Kowa Pharmaceuticals, Nevro; Consultant: Collegium, Scilex, Vertex, Xgene Pharma, Tris, PainScripts, Nevro; Other: Lundbeck and Teva; Stock Holder (publicly traded company): Pfizer and Trevana
- Amy Clouse, MD, FAAFP
- Speaker: Astellas Pharmacueticals; Stock Holder (publicly traded company): Eli Lilly; Novo Nordisk
- Oscar A. de Leon-Casasola, MD
- Consultant: Merck Pharmaceuticals, Vertex Pharmaceuticals.
- Stephanie Faubion, MD, MBA, FACP, NCMP, IF
- Information to come
- Katherine E. Galluzzi, DO, CMD, FACOFP
- Advisor: Lilly
- Aubrey J. Grant, MD, FACC
- No relevant financial relationships disclosed.
- Jacob H. Johnson, MD
- No relevant financial relationships disclosed
- Pamela Kushner, MD, FAAFP
- Advisor: GlaxoSmithKline, Novo Nordisk, AstraZeneca, Lilly, Abbott, Haleon, Bausch/SALIX, Corcept, Boehringer Ingelheim; Speaker: Novo Nordisk, Lilly, Boehringer Ingelheim, AstraZeneca, GlaxoSmithKline, Abbott, Phathom, Bausch/SALIX, Intuity, Pfizer, and Janssen.
- Jacob Levitt, MD, FAAD
- No relevant financial relationships disclosed.
- Joynita R. Nicholson, DO, DABOM, FOMA
- No relevant financial relationships disclosed.
- Philip Schoenfeld, MD, MSEd, MSc
- Speaker: Ironwood Pharmaceuticals, Ardelyx Pharmaceuticals, Phathom Pharmaceuticals, AbbVie Pharmaceuticals; Consultant: Phathom Pharmaceuticals, Ardelyx Pharmaceuticals
- Pierre N. Tariot, MD
- Advisor: AbbVie, Athira, Cognition Therapeutics; Consultant: Acadia, Bristol Myers-Squibb, Corium, ImmunoBrain, Janssen, Maplight, Novartis; Speaker: Astellas; Stock Holder (publicly traded company): Eli Lilly, Novo Nordisk
- Charles Vega, MD, FAAFP
- Consultant: Boehringer Ingelheim, and Exact Sciences
- Karol E. Watson, MD, PhD
- Consultant: Amarin, Amgen, Boehringer Ingelheim, Eli Lilly, Novartis
Other Disclosures
All other non-faculty contributors involved in the moderating, planning, development, editing and review of the content have disclosed no relevant financial relationships.